+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 30 Actively Recruiting clinical trials

E

Actively Recruiting

This research aims to evaluate the efficacy and safety of rilzabrutinib in adults diagnosed with active Immunoglobulin G4-related disease IgG4-RD. It is a Phase 3, randomized, double-blind, placebo-controlled study that will measure the time to clinical disease flare and other important efficacy and safety outcomes over a 52-week treatment period. The study includes adult participants aged 18 and older who have a confirmed diagnosis of IgG4-RD and active disease in at least one organ. Participants will be randomly assigned to receive either rilzabrutinib tablets or a placebo, both taken orally, over a 52-week double-blind treatment period. The study also includes a screening period of 4 to 6 weeks before treatment, followed by a 2-week follow-up after the treatment phase. An optional open-label extension lasting 108 weeks is available for participants who complete the main study. The total study duration may extend up to 60 weeks for the main phases. Throughout the study, participants will attend up to 16 visits during the main treatment period and additional visits if they join the extension phase. Researchers will monitor disease activity and flare rates using clinical assessments, imaging procedures such as CT, MRI, PET, or ultrasound, laboratory tests, ECGs, and safety evaluations including adverse event monitoring. Outcomes include flare-free rates, disease activity scores, glucocorticoid use, and safety parameters, with follow-up continuing beyond the treatment phase to assess long-term effects.

Age: 18Years +All GendersPhase 3
95 locations
S

Actively Recruiting

Researchers are studying the effects of the drug leflutrozole on semen quality in men aged 18 to 49 years with low testosterone levels. This phase 2 clinical trial aims to find out whether leflutrozole can improve semen quality and what side effects participants may experience compared to a placebo. The trial is sponsored by ReproNovo Aps and focuses on testicular function and hormone levels. Participants will be randomly assigned to receive one of three doses of leflutrozole 0.05 mg, 0.1 mg, or 0.3 mg or a placebo. The medication is taken orally once a week for 16 weeks. The study is double-blind, meaning neither the participants nor the researchers know who receives the drug or placebo. Checkups and tests occur every 4 weeks during the treatment period. Men in the trial will provide semen samples to measure sperm count, motility, and other quality markers. Blood tests will monitor hormone levels such as testosterone and estradiol, as well as safety markers including prostate-specific antigen and ECG readings. Questionnaires will assess changes in libido and energy. Researchers will track adverse events throughout the 16 weeks to evaluate safety and effectiveness.

Age: 18Years - 49YearsMALEPhase 2
4 locations
E

Actively Recruiting

Researchers are evaluating the effect of pegloticase given by two different methods along with methotrexate in adults with uncontrolled gout. This phase 3 trial compares subcutaneous under the skin injections of pegloticase at 18 mg every two weeks with intravenous into a vein injections of pegloticase at 8 mg every two weeks, both combined with weekly methotrexate. The main goal is to see which approach better maintains low serum uric acid levels during the sixth month. Participants will be randomly assigned to receive either pegloticase by subcutaneous injection or by intravenous infusion, both administered every two weeks, alongside oral methotrexate taken weekly. The trial is double-blind, meaning neither participants nor researchers know which form of pegloticase is given. Methotrexate is given orally concurrently. Treatment continues through at least six months with ongoing evaluations. During the study, participants will have regular assessments to monitor their response to treatment, including blood tests to measure serum uric acid levels and pegloticase concentrations. Safety will be closely observed, including monitoring for injection site reactions, infusion reactions, and anaphylaxis up to 48 weeks. The primary outcome measures participants who maintain normalized uric acid levels during Month 6, with follow-up lasting up to 48 weeks. Total participation may extend to the study completion in June 2028.

Age: 18Years +All GendersPhase 3
75 locations
E

Actively Recruiting

Researchers are evaluating BRX011, an oral medication taken once daily, for adults with geographic atrophy secondary to age-related macular degeneration. This phase 12 study aims to assess both the safety and effectiveness of BRX011 compared to a placebo over nearly two years. The study focuses on how well the treatment slows the progression of geographic atrophy. Participants will be randomly assigned to receive either BRX011 capsules or placebo capsules daily. The study lasts 96 weeks and includes multiple visits to monitor health and treatment response. Safety is closely monitored with regular checks including vital signs, lab tests, eye exams, and imaging to detect any adverse effects. During the study, participants will undergo evaluations such as visual acuity testing and imaging of the eye to measure changes in geographic atrophy area. Researchers will track the annual rate of change in the square root of the geographic atrophy area as the primary outcome. Secondary measures include changes in vision under low light and best-corrected visual acuity. Participant well-being is monitored throughout, and the study is sponsored by Biojiva LLC.

Age: 55Years +All GendersPhase 1Phase 2
17 locations
E

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and lasting effects of a single intravitreal injection of 4D-150 compared to aflibercept in adults with diabetic macular edema DME. The study is a Phase 3, randomized, double-masked, active-controlled trial designed to assess visual acuity changes and disease severity over one year. Participants will be randomly assigned to receive either a single dose of 4D-150 or aflibercept eye injections. The 4D-150 treatment is given once on Day 1, while aflibercept is administered at appropriate visits. The study lasts for 52 weeks, focusing on visual outcomes and the need for additional aflibercept injections after the initial treatments. Throughout the study, participants will undergo regular eye examinations to monitor visual acuity using the Early Treatment Diabetic Retinopathy Study ETDRS scale and assessments of diabetic retinopathy severity. Researchers will also track the number of aflibercept injections needed after Week 4. Safety and durability of the treatments will be closely observed during the one-year follow-up period.

Age: 18Years +All GendersPhase 3
87 locations
P

Actively Recruiting

Researchers are studying PRL-02 depot, a potential injectable treatment for men with advanced prostate cancer, including those whose cancer has returned or not responded to previous treatments. The trial aims to evaluate the safety and tolerability of PRL-02 depot alone or combined with enzalutamide, as well as to determine the appropriate dose. This Phase 1 study is sponsored by Astellas Pharma Global Development, Inc. and focuses on men with metastatic or biochemical relapse forms of prostate cancer. Participants will be divided into groups receiving different doses of PRL-02 depot injected into a muscle every 12 weeks. They will also take daily oral doses of either dexamethasone, prednisone, or enzalutamide depending on their study group and prior treatments. The study has two parts dose escalation with small groups receiving increasing doses, and dose expansion involving men previously treated with specific hormone therapies. During the trial, men will visit the clinic multiple times for health checks, scans, and blood tests to monitor side effects, disease progression, and testosterone suppression. After the final visit, those whose cancer has not worsened will continue to have periodic health assessments and scans. The main outcomes include tracking dose limiting toxicities and adverse events over up to four years, along with detailed pharmacokinetic and response measurements.

Age: 18Years +MALEPhase 1
25 locations
P

Actively Recruiting

Researchers are evaluating brenipatide, a drug given as a subcutaneous injection, compared to a placebo to understand its effects and safety in adults with moderate-to-severe Alcohol Use Disorder AUD. The study is a Phase 3, multicenter, randomized, double-blind trial sponsored by Eli Lilly and Company. The trial aims to assess changes in drinking patterns over a period of up to 56 weeks. Participants receive escalating doses of the study drug or placebo administered by subcutaneous injection. The study includes two experimental periods with LY3537031 and a placebo group. Participants will self-inject the study intervention, keep diaries, and complete questionnaires throughout the trial. The trial design includes random assignment to one of the study groups, and treatment is monitored over the full 56 weeks. During the study, participants will attend regular visits to monitor their alcohol consumption using the Timeline Followback method, assess alcohol cravings with the Penn Alcohol Craving Scale, and evaluate health outcomes including body weight and quality of life measures. Researchers will also study the drugs pharmacokinetics and the presence of anti-drug antibodies. Participation lasts about 56 weeks, with ongoing safety and efficacy assessments throughout this period.

Age: 18Years - 75YearsAll GendersPhase 3
117 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of nipocalimab compared to placebo in adults with moderate to severe systemic lupus erythematosus SLE, a long-term autoimmune disease where the immune system attacks healthy tissues causing inflammation in various organs. This phase 3, randomized, double-blind study aims to determine how well nipocalimab works alongside standard care treatments in managing SLE symptoms and disease activity. Participants will receive either nipocalimab or placebo combined with standard care treatments during a 52-week double-blind period. After this, eligible participants from both groups can join an open-label extension where they will continue to receive nipocalimab until Week 156 or until the study intervention is stopped. This design allows comparison of nipocalimabs effects versus placebo and longer-term safety and effectiveness in an open-label setting. Throughout the study, participants undergo regular assessments including disease activity indexes, joint evaluations, and fatigue scores. Researchers will track the percentage of participants achieving a standard SLE response measure at Week 52 and monitor changes in oral glucocorticoid use, joint pain, and flare-free status. Safety and treatment adherence are closely monitored across study visits, with data collected up to 3 years for long-term evaluation.

Age: 18Years - 75YearsAll GendersPhase 3
272 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of an investigational treatment called T3011 in people with non-muscle invasive bladder cancer NMIBC that has not responded to standard therapies like BCG or chemotherapy. This Phase II study focuses on patients with high-risk or intermediatehigh-risk NMIBC who have limited treatment options after previous therapies have failed. Participants receive T3011 as an injection into the bladder once a week for six weeks during an induction phase. After a rest period, a 3-month evaluation determines if further treatment is needed. Those with no recurrence or complete response enter a maintenance phase where T3011 is given every three weeks for up to about 24 months. The study includes different cohorts based on cancer characteristics and prior treatments. Throughout the study, participants undergo regular cystoscopy, urine cytology, and imaging as needed every three months to monitor disease status. Researchers will track response rates, recurrence-free survival, and any treatment-related adverse events for up to 24 months. Participants are expected to comply with study procedures and follow-up assessments during this time.

Age: 18Years +All GendersPhase 2
9 locations
E

Actively Recruiting

Psoriatic arthritis PsA is a chronic inflammatory condition affecting the joints and skin of people with psoriasis PsO. This research aims to evaluate how well the drug zasocitinib works in adults with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The study is a phase 3 trial comparing zasocitinib to an active comparator and placebo to assess treatment effects and safety. Participants are randomly assigned to one of four groups. One group receives zasocitinib Dose A orally once daily for up to 52 weeks, another group receives zasocitinib Dose B once daily for the same period, a third group receives the active comparator capsules twice daily for up to 52 weeks, and the fourth group receives placebo once daily for 16 weeks followed by zasocitinib Dose A or B from Week 16 to Week 52. This design allows comparison between different doses, placebo, and active treatments. During the study, participants will be monitored regularly with evaluations including joint assessments and skin lesion checks. Researchers will measure responses such as improvement in arthritis symptoms using the American College of Rheumatology 20 ACR20 response at Week 16 as the primary outcome. Secondary measures include skin improvement and various quality of life and disease activity scores. The study duration for participants is up to 60 weeks, including treatment and follow-up, to assess both efficacy and safety of the treatments.

Age: 18Years +All GendersPhase 3
188 locations

1-10 of 30

1